Why the study?
It was unknown whether lean metabolic dysfunction-associated steatotic liver disease is associated with the progression of carotid atherosclerosis in patients with type 2 diabetes mellitus.
Does lean MASLD increase the risk of carotid atherosclerosis progression in patients with type 2 diabetes mellitus compared to lean patients without MASLD?
Population
828 patients with type 2 diabetes mellitus
Comparison
Lean MASLD vs non-lean MASLD vs non-lean without MASLD vs lean without MASLD
Design
Cohort study
Follow-up
6–8 years
Key result
Lean metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes was associated with an increased risk of carotid atherosclerosis progression (aOR 2.57; P=0.005).
Authors
Loading...
Should not yet change vascular risk management in T2DM; leaves open need for prospective trials on lean MASLD.
Cohort (n=828)
Does lean MASLD increase the risk of carotid atherosclerosis progression in patients with type 2 diabetes mellitus compared to lean patients without MASLD?
Effect estimate: aOR 2.57
p-value: p=0.005
In patients with type 2 diabetes, both lean and non-lean MASLD are associated with an increased risk of carotid atherosclerosis progression compared to lean patients without MASLD.
Kim et al. (2025) conducted a cohort in Type 2 diabetes mellitus (n=828). Lean metabolic dysfunction-associated steatotic liver disease (MASLD) vs. Lean without MASLD was evaluated on Progression of carotid atherosclerosis (appearance of new carotid plaque lesions) (aOR 2.57, p=0.005). Lean metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes was associated with an increased risk of carotid atherosclerosis progression (aOR 2.57; P=0.005).